phrykt

MiNK Therapeutics, Inc. (INKT): who owns it and who trades it

As of Oct 30, 2026, INKT insiders reported 9 open-market sales worth $120K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Buell (CEO), with $73.3K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, INKT insiders reported $0 of open-market purchases and $120K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$120K
9 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 12, 2026
Filed Oct 14, 2026

Purchases and sales by month

$73.3K$73.3KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 12, 2026Jennifer BuellCEOSale6,938$10.56$73.3KForm 4
Jun 4, 2026Barbara RyanDirectorSale1,000$12.80$12.8KForm 4
Jun 4, 2026Barbara RyanDirectorSale500$12.68$6.3KForm 4
Mar 10, 2026Barbara RyanDirectorSale500$15.30$7.7KForm 4
Mar 10, 2026Barbara RyanDirectorSale500$15.57$7.8KForm 4
Mar 10, 2026Barbara RyanDirectorSale300$15.28$4.6KForm 4
Mar 9, 2026Barbara RyanDirectorSale200$10.17$2KForm 4
Mar 2, 2026Barbara RyanDirectorSale100$10.83$1.1KForm 4
Feb 27, 2026Barbara RyanDirectorSale400$10.86$4.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jennifer BuellChief Executive Officer, Director–$73.3KOct 12, 2026
Barbara RyanDirector–$46.6KJun 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

INKT short interest

Low short interest. 1.1% of INKT shares are sold short: about 1 share in 93. Over the last 12 reports the number of shares short went down 55%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 55,094 INKT shares were sold short, 1.1% of the shares outstanding, up 15.3% from the report before. At the average daily volume of 12,851 shares, buying them all back would take about 4.3 trading days (days to cover).

Shares short, % of all shares

1.08%May 15Oct 302.71%

Days to cover

4.3May 15Oct 3010.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202655,0941.08%+15%12,8514.3
Oct 15, 202647,7780.94%-4%19,9742.4
Sep 30, 202649,5830.97%-13%15,8983.1
Sep 15, 202657,1361.12%-12%18,4213.1
Aug 31, 202664,9651.27%-17%9,5066.8
Aug 14, 202678,3201.53%-17%8,6669.0
Jul 31, 202694,0921.89%-6%10,0449.4
Jul 15, 202699,5742.01%-11%14,6256.8
Jun 30, 2026112,4592.26%-3%18,5866.0
Jun 15, 2026115,8352.33%-1%42,4322.7
May 29, 2026116,4452.34%-5%53,1042.2
May 15, 2026122,9572.48%+27%27,6824.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

MiNK Therapeutics company events

MiNK Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Aug 13, 2026.

  1. Aug 13, 2026ResultsReleased financial results. Filing
  2. Jun 23, 2026VoteReported shareholder vote results. Filing
  3. May 15, 2026ResultsReleased financial results. Filing
  4. Mar 31, 2026ResultsReleased financial results. Filing
  5. Mar 27, 2026AnnouncementIn response to recent investor inquiries regarding third-party postings concerning potential combination trials involving agenT-797, MiNK Therapeutics, Inc. is providing the following clarification: The Company is actively engaged in discussions with multiple parties regarding potential combination… Filing
  6. Mar 19, 2026LeadershipMiNK Therapeutics Inc.'s Board of Directors appointed Melissa Orilall, Agenus Inc.'s current Vice President, Global Financial Operations to serve as the Company's Principal Financial Officer. Filing
  7. Jan 2, 2026LeadershipRobert Kadlec, MD, resigned from the Board of Directors of MiNK Therapeutics, Inc., including all committees thereof, effective December 29, 2025, in connection with his acceptance of a senior public service role within the United States government as Assistant Secretary of War for Nuclear… Filing
  8. Dec 8, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

MiNK Therapeutics financials

Questions about MiNK Therapeutics, Inc. (INKT) stock

Are INKT insiders buying or selling?

In the last 12 months, INKT insiders reported no open-market purchases and 9 sales worth $120K. The latest trade was on Oct 12, 2026. See every trade.

What is the short interest in INKT?

As of Oct 30, 2026, 55,094 INKT shares were sold short, 1.1% of the shares outstanding, up 15.3% from the report before. At the average daily volume of 12,851 shares, buying them all back would take about 4.3 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.